Biopharmaceutical Informatics: Learning to Discover Developable Biotherapeutics - Softcover

Softcover

ISBN 10: 1032291680 ISBN 13: 9781032291680

Verlag: CRC Press, 2026

Inhaltsangabe

This book describes ways to invent and commercialize biomedicines in a more time and cost-efficient manner. Failure to translate a discovery into a marketed drug denies us an opportunity to improve the lives of patients who do not have access to effective therapies. Here, the authors provide a greater understanding of biopharmaceutical informatics.

Über diesen Titel

Über die Autorin bzw. den Autor

Dr. Sandeep Kumar is currently a Distinguished Fellow (Executive Director) at the department of Computational Science in Moderna Therapeutics, Cambridge, MA where he leads Molecular Design and Modeling team. Sandeep Kumar holds a Ph.D. in Computational Biophysics and has over 25 years of experience researching protein structure – Function relationships. Sandeep Kumar has so far contributed towards more than 100 research articles, reviews, book chapters, and has previously edited a book entitled “Developability of Biotherapeutics: Computational Approaches”. Sandeep has been contributing towards discovery and development of numerous monoclonal antibodies, antibody drug conjugates, bispecific and multi-specific modalities, as well as vaccines. Based on the insights gained from these experiences, Sandeep has been advocating for Biopharmaceutical Informatics, a strategic vision dedicated to synergistic use of computation and experimentation towards a cost effective and more efficient discovery and development of Biotherapeutics. More recently, he is promoting the concept of DAbI (Discovery of Antibodies in silico) where he sees an opportunity for generative AI to not only accelerate biopharmaceutical drug design but also to expand the antigen space druggable by antibody-based biotherapeutics.

Dr. Andrew Nixon is currently Vice President, Biotherapeutics Molecule Discovery at Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. Andy earned his Ph.D. in Physical Biochemistry from the University of London for studies completed at the MRC’s National Institute for Medical Research. Andy has over 20 years of experience in biologic drug discovery and has contributed to over 100 antibody discovery programs resulting in numerous clinical candidates and approved biologics including TAKHZYRO, a fully human antibody inhibitor of plasma kallikrein.

Details zur Ausgabe

• Verlag: CRC Press
• Erscheinungsdatum: 2026
• Sprache: Englisch
• ISBN 10: 1032291680
• ISBN 13: 9781032291680
• Einband: Taschenbuch
• Anzahl der Seiten: 368
• Herausgeber: Nixon Andrew, Kumar Sandeep
• Kontakt zum Hersteller: CRC Press; https://www.routledge-ny.com; ; 6000 BROKEN SOUND PARKWAY, NW SUITE 300; BOCA RATON; FL; 33487; USA
• Verantwortliche Person: Nicht verfügbar